Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria

International Journal of Antimicrobial Agents

Volumn 43, Issue 1, 2014, Pages 52-59

  Pontikis, Konstantinos ^a   Karaiskos, Ilias ^b   Bastani, Styliani ^c   Dimopoulos, George ^a   Kalogirou, Michalis ^d   Katsiari, Maria ^e   Oikonomou, Angelos ^a   Poulakou, Garyphallia ^a   Roilides, Emmanuel ^f   Giamarellou, Helen ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b HYGEIA HOSPITAL   (Greece)

^c Hospital of Arta   (Greece)

^d UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^e Konstantopoulio Hospital   (Greece)

^f Aristotle University and Hippokration General Hospital   (Greece)

Author keywords

Critically ill; Fosfomycin; Klebsiella; PDR; Pseudomonas; XDR

Indexed keywords

CARBAPENEMASE; COLISTIN; FOSFOMYCIN; TIGECYCLINE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIAL CLEARANCE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CASE STUDY; CAUSE OF DEATH; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DIARRHEA; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOKALEMIA; INTENSIVE CARE UNIT; KLEBSIELLA INFECTION; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; MULTICENTER STUDY; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RASH; THROMBOCYTOPENIA; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

CRITICALLY ILL; FOSFOMYCIN; KLEBSIELLA; PDR; PSEUDOMONAS; XDR;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; COLISTIN; CRITICAL ILLNESS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; FOSFOMYCIN; HUMANS; INTENSIVE CARE UNITS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; MINOCYCLINE; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

EID: 84890804676     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.09.010     Document Type: Article

References (30)

1. H. Hanberger, C.G. Giske, and H. Giamarellou When and how to cover for resistant Gram-negative bacilli in severe sepsis and septic shock Curr Infect Dis Rep 13 2011 416 425
2. M.E. Falagas, P.I. Rafailidis, E. Ioannidou, V.G. Alexiou, D.K. Matthaiou, and D.E. Karageorgopoulos Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients Int J Antimicrob Agents 35 2010 194 199
3. A. Antoniadou, F. Kontopidou, G. Poulakou, E. Koratzanis, I. Galani, and E. Papadomichelakis Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster J Antimicrob Chemother 59 2007 786 790
4. F. Kontopidou, D. Plachouras, E. Papadomichelakis, G. Koukos, I. Galani, and G. Poulakou Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients Clin Microbiol Infect 17 2011 E9 E11
5. R. Raz Fosfomycin: an old-new antibiotic Clin Microbiol Infect 18 2012 4 7
6. T.C. Horan, M. Andrus, and M.A. Dudeck CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting Am J Infect Control 36 2008 309 332 [Erratum in: Am J Infect Control 2008;36:655]
7. R.P. Dellinger, M.M. Levy, J.M. Carlet, J. Bion, M.M. Parker, and R. Jaeschke Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008 Crit Care Med 36 2008 296 327
8. A-P. Magiorakos, A. Srinivasan, R.B. Carey, Y. Carmeli, M.E. Falagas, and C.G. Giske Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance Clin Microbiol Infect 18 2012 268 281
9. American Thoracic Society; Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia Am J Respir Crit Care Med 171 2005 388 416
10. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. Document M100-S22 2012 CLSI Wayne, PA
11. ® label information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 021821s027lbl.pdf [accessed 16 July 2013].
12. K. Lee, Y.S. Lim, D. Yong, J.H. Yum, and Y. Chong Evaluation of the Hodge test and the Imipenem-EDTA double-disk synergy test for differentiating metallo-β-lactamase-producing isolates of Pseudomonas spp and Acinetobacter spp. J Clin Microbiol 41 2003 4623 4629
13. L. Poirel, T.R. Walsh, V. Cuvillier, and P. Nordmann Multiplex PCR for detection of acquired carbapenemase genes Diagn Microbiol Infect Dis 70 2011 119 123
14. R. Bellomo, C. Ronco, J.A. Kellum, R.L. Mehta, and P. Palevsky Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group Crit Care 8 2004 R204 R212
15. M.E. Falagas, S. Maraki, D.E. Karageorgopoulos, A.C. Kastoris, E. Mavromanolakis, and G. Samonis Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin Int J Antimicrob Agents 35 2010 240 243
16. M. Popovic, D. Steinort, S. Pillai, and C. Joukhadar Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis 29 2010 127 142
17. M. Souli, I. Galani, S. Boukovalas, M.G. Gourgoulis, Z. Chryssouli, and K. Kanellakopoulou In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development Antimicrob Agents Chemother 55 2011 2395 2397
18. M.E. Falagas, K.P. Giannopoulou, G.N. Kokolakis, and P.I. Rafailidis Fosfomycin: use beyond urinary tract and gastrointestinal infections Clin Infect Dis 46 2008 1069 1077
19. A. Dinh, J. Salomon, J.P. Bru, and L. Bernard Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria Scand J Infect Dis 44 2012 182 189
20. A. Michalopoulos, S. Virtzili, P. Rafailidis, G. Chalevelakis, M. Damala, and M.E. Falagas Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation Clin Microbiol Infect 16 2010 184 186
21. A. Apisarnthanarak, and L.M. Mundy L.M. Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin Int J Antimicrob Agents 39 2012 271 272
22. M. Souli, I. Galani, A. Antoniadou, E. Papadomichelakis, G. Poulakou, and T. Panagea An outbreak of infection due to β-lactamase Klebsiella pneumoniae carbapenemase 2-producing K pneumoniae in a Greek university hospital: molecular characterization, epidemiology, and outcomes Clin Infect Dis 50 2010 364 373
23. O. Zarkotou, S. Pournaras, P. Tselioti, V. Dragoumanos, V. Pitiriga, and K. Ranellou Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment Clin Microbiol Infect 17 2011 1798 1803
24. E. Mouloudi, E. Protonotariou, A. Zagorianou, E. Iosifidis, A. Karapanagiotou, and T. Giasnetsova Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes Infect Control Hosp Epidemiol 31 2010 1250 1256
25. D.E. Karageorgopoulos, R. Wang, X-H. Yu, and M.E. Falagas Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens J Antimicrob Chemother 67 2012 255 268
26. A.I. Nilsson, O.G. Berg, O. Aspevall, G. Kahlmeter, and D.I. Andersson Biological costs and mechanisms of fosfomycin resistance in Escherichia coli Antimicrob Agents Chemother 47 2003 2850 2858
27. A. Florent, R-M. Chichmanian, E. Cua, and C. Pulcini Adverse events associated with intravenous fosfomycin Int J Antimicrob Agents 37 2011 82 83
28. C. Yanagida, K. Ito, I. Komiya, and T. Horie Protective effect of fosfomycin on gentamicin-induced lipid peroxidation of rat renal tissue Chem Biol Interact 148 2004 139 147
29. M. Tumbarello, P. Viale, C. Viscoli, E.M. Trecarichi, F. Tumietto, and A. Marchese Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K.pneumoniae: importance of combination therapy Clin Infect Dis 55 2012 943 950
30. L.S. Tzouvelekis, A. Markogiannakis, M. Psichogiou, P.T. Tassios, and G.L. Daikos Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions Clin Microbiol Rev 25 2012 682 707